Advances in Treating Metastatic Bone Cancer
CME Monograph - September 2008
This CME activity was intended for oncologists, urologists and other medical professionals who assess, treat and counsel patients with metastatic bone cancer.
The activity was produced in print and online. Links to the online activity and printable PDF are located below.
The activity is no longer active.
Program Faculty: Robert E. Coleman, MD, FRCP, Professor of Medical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom; Theresa A. Guise, MD, Endocrinology & Medicine, University of Virginia, Charlottesville, Virginia; Allan Lipton, MD, Penn State University, Milton S. Hershey Medical Center, Hershey, Pennsylvania; and G. David Roodman, MD, PhD, Director of the Bone Biology Center, Director of the Myeloma Program, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Statement of Need
The skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients. Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spread to bone have contributed to the development of several important new drugs targeting these processes, and focused research on further understanding the biology and targets involved in metastasis and bone loss. Oncologists, surgeons and other medical professionals need to be able to assess important new data and recommendations related to preventing bone metastasis, predicting who is at risk for skeletal-related events, and recent advances in clinical research in bone-targeted therapies so that they can more effectively counsel and treat their patients.
Educational Grant Support
Supported by educational grants provided by Novartis Pharmaceuticals, Amgen Inc. and Merck & Co, Inc.
Sponsorship
CME sponsorship was provided by InforMEDical Communications, Inc.
